Skip to main content

Table 1 Subscales of health-related quality of life by patients’ characteristics at baseline and responses to TKI therapy within 1 year

From: Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

Variable

No (%)

PF

RP

BP

GH

PCS

VT

SF

RE

MH

MCS

Median

P

Median

P

Median

P

Median

P

Median

P

median

P

Median

P

Median

P

Median

P

Meidan

P

Gender

  

0.61

 

0.75

 

0.58

 

0.44

 

0.84

 

0.36

 

0.024

 

0.18

 

0.91

 

0.087

 Male

35 (59.3)

56.46

 

48.15

 

50.24

 

52.62

 

49.67

 

58.61

 

52.53

 

54.81

 

58.94

 

54.13

 

 Female

24 (40.7)

56.46

 

51.88

 

50.25

 

55.84

 

51.14

 

61.00

 

59.55

 

54.81

 

58.06

 

58.76

 

Age

  

0.056

 

0.66

 

0.55

 

0.78

 

0.62

 

0.96

 

0.73

 

0.14

 

0.42

 

0.85

 < 40 years

33 (55.9)

56.46

 

48.15

 

54.15

 

56.58

 

50.29

 

58.61

 

59.55

 

54.81

 

57.18

 

56.54

 

 ≥ 40 years

26 (44.1)

53.94

 

51.88

 

46.34

 

53.86

 

50.31

 

58.61

 

52.53

 

49.67

 

58.94

 

55.40

 

Education

  

0.36

 

0.85

 

0.40

 

0.54

 

0.64

 

0.19

 

0.66

 

0.14

 

0.026

 

0.030

 ≥ Bachelor degree

24 (40.7)

56.46

 

48.15

 

54.15

 

55.35

 

51.94

 

62.20

 

52.53

 

54.81

 

60.70

 

52.60

 

 < Bachelor degree

35 (59.3)

56.46

 

55.60

 

46.34

 

55.10

 

49.67

 

58.61

 

59.55

 

54.81

 

55.42

 

59.58

 

TKI used

  

0.52

 

0.71

 

0.98

 

0.042

 

0.38

 

0.87

 

0.49

 

0.49

 

0.23

 

0.40

 Imatinib

31 (52.5)

56.46

 

55.60

 

54.15

 

52.62

 

49.01

 

58.61

 

52.53

 

54.81

 

58.94

 

57.29

 

 Nilotinib

28 (47.5)

57.73

 

48.15

 

50.24

 

58.32

 

52.21

 

59.81

 

59.55

 

54.81

 

57.18

 

52.93

 

Sokal risk

  

0.63

 

0.31

 

0.67

 

0.48

 

0.17

 

0.29

 

0.32

 

0.84

 

0.47

 

0.99

 Low

28 (47.5)

56.46

 

48.15

 

48.29

 

54.60

 

48.35

 

58.61

 

52.53

 

54.81

 

58.94

 

56.07

 

 Intermediate / High

18 (30.5) /13 (22.0)

56.46

 

55.60

 

54.15

 

55.10

 

52.52

 

58.61

 

59.55

 

54.81

 

57.18

 

56.54

 

Response at 3 months

  

0.35

 

0.26

 

0.30

 

0.36

 

0.20

 

0.71

 

0.94

 

0.41

 

0.83

 

0.80

 Optimal

44 (74.6)

56.46

 

48.15

 

48.29

 

52.62

 

49.20

 

58.61

 

56.04

 

54.81

 

58.06

 

56.60

 

 Warning / Failure

9 (15.3) /6 (10.1)

58.99

 

55.60

 

54.15

 

59.06

 

52.28

 

58.61

 

52.53

 

54.81

 

58.94

 

55.22

 

Response at 6 months

  

0.52

 

0.45

 

0.77

 

1.0

 

0.35

 

0.44

 

0.52

 

0.89

 

0.74

 

0.92

 Optimal

43 (72.9)

56.46

 

48.15

 

54.15

 

55.10

 

49.38

 

58.61

 

52.53

 

54.81

 

58.94

 

55.46

 

 Warning / Failure

9 (15.3) /7 (11.9)

57.73

 

55.60

 

48.29

 

55.35

 

51.29

 

59.81

 

56.04

 

54.81

 

56.30

 

57.09

 

Response at 12 months

  

0.65

 

0.85

 

0.49

 

0.92

 

0.29

 

0.43

 

0.91

 

0.37

 

0.64

 

0.40

 Optimal

28 (48.3)

56.46

 

48.15

 

48.29

 

53.86

 

48.74

 

59.81

 

56.04

 

54.81

 

58.06

 

57.11

 

 Warning / Failure

16 (27.6) / 14 (24.1)

56.46

 

55.60

 

54.15

 

56.58

 

52.12

 

58.61

 

52.53

 

54.81

 

58.94

 

55.22

 
  1. P value in bold and italics are significant with P < 0.05